CELLector device to collect CD8 T-lymphocytes data

AISX (Santa Clara, Calif.) reported Phase II data using its CELLector device, showing significant elevation of a class of lymphocytes thought to be associated with delayed disease progression. No clear effect on viral burden, the end point, was detected.

Because the participants were asymptomatic, with CD4 counts over 300 on average, the company said that it proved to be difficult to show changes in viral burden. ...